Repligen (RGEN)
(Real Time Quote from BATS)
$155.89 USD
-5.78 (-3.58%)
Updated Aug 5, 2024 10:28 AM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 81 - 100 ( 208 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Ireland Bioprocess Tour Recap: Growth Not Slowing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Confidence Builder - Core Beat, BioProcess Strong, COVID Lower
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Life Science Tools & Services - Alert: MEDP Results and VC Funding Show CRO Debate Continuing and BioProcess Growth Visible
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
2022 Life Sciences & MedTech Investor Forum
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
4Q21 with Historically High Fiscal Year Guide
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Growth Visibility Increasing; Valuation Reaching Historical Lows
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Component by Component - BioFlex Acquisition - All Makes Sense
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department